Erasca (NASDAQ:ERAS) Shares Gap Up – Should You Buy?

Erasca, Inc. (NASDAQ:ERAS)’s share price gapped up prior to trading on Monday . The stock had previously closed at $17.63, but opened at $18.41. Erasca shares last traded at $17.1180, with a volume of 245,659 shares changing hands.

Analyst Ratings Changes

ERAS has been the topic of several research analyst reports. Mizuho cut their price target on shares of Erasca from $28.00 to $26.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 12th. HSBC set a $20.00 price objective on Erasca in a report on Tuesday, July 14th. Wall Street Zen cut Erasca from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Wolfe Research set a $16.00 target price on Erasca in a report on Thursday, June 4th. Finally, Guggenheim upped their target price on Erasca from $20.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.09.

Erasca Price Performance

The firm’s 50 day moving average price is $17.74 and its two-hundred day moving average price is $15.32. The firm has a market cap of $6.09 billion, a price-to-earnings ratio of -18.27 and a beta of 0.66.

Erasca (NASDAQ:ERAS) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). On average, analysts anticipate that Erasca, Inc. will post -0.48 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of ERAS. BlackRock Inc. purchased a new position in Erasca in the 2nd quarter valued at $387,544,000. ARCH Venture Management LLC purchased a new position in Erasca during the 2nd quarter worth $129,917,324,000. Spruce Street Capital LP acquired a new stake in shares of Erasca in the 4th quarter worth $14,469,000. Janus Henderson Group PLC acquired a new stake in shares of Erasca in the 1st quarter worth $59,988,000. Finally, Commodore Capital LP purchased a new stake in shares of Erasca in the first quarter valued at about $51,372,000. Institutional investors and hedge funds own 67.78% of the company’s stock.

About Erasca

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.